500 S 52nd St
Rogers, AR
p: 479-254-9662
f: 479-254-9652
The brief descriptions below are designed to familiarize you with our staff's training, professional credentials and work experience.
About Dr. Cheryl Hull
Dr. Cheryl A. Hull is a native of Northwest Arkansas. Her parents moved to Rogers, Arkansas when she was 9 weeks old. She lived in Rogers through junior high school attending both St. Vincent De Paul and Shiloh Christian School. Later, she attended Gentry High School where she was a key player on a state basketball championship team. Dr. Hull is also a pianist who trained under Mrs. Betty Sutton of Rogers.
Northwest Arkansas continued to be Dr. Hull's home throughout her secondary education. She studied at the University of Arkansas in Fayetteville and received a Bachelor's degree in Biology (Magna Cum Laude) and a Master's in Microbiology (with honors). She then continued her studies in Little Rock where she attended medical school graduating with honors. She then completed her internship in Internal Medicine, and a residency in Dermatology at the University of Arkansas for Medical Sciences. She received numerous awards, scholarships and honors during this time and published several scientific papers in major medical journals.
With a strong desire to return to Northwest Arkansas, Dr. Hull moved home to practice Dermatology. In addition, her husband is a physician at the Veteran's Hospital in Fayetteville. In addition, her father, Dr. Robert R. Hull, is a family medicine physician who has been in private practice in Rogers for over 35 years. The rest of Dr. Hull's family, including 2 older brothers and their families, a younger sister and her family live in Northwest Arkansas.
Susie Reed, R.N.
Susie is an aesthetic nurse injector with over 16 years experience in the cosmetic industry. She specializes in Botox, lip enhancement and cosmetic dermal fillers, such as Juvederm, Radiesse, Restylane, Perlane and Sculptra. Susie also performs many other aesthetic procedures that include sclerotherapy for leg veins, microdermabrasion, chemical peels and laser treatments for hair removal, and skin rejuvenation.
Dr.Cheryl Hull CV
| EXPERIENCE | |
| April 2006 Hull Dermatology Rogers, AR Dermatologist General medical adult and pediatric dermatology Surgical Dermatology Cosmetic Dermatology |
|
| July 2005 Ubben Dermatology Rogers, AR Dermatologist General medical adult and pediatric dermatology Surgical dermatology Cosmetic dermatology |
|
| July 2002-June 2005 Dermatology Residency Little Rock, AR Residency Chief resident in Dermatology at University of Arkansas for Medical Sciences |
|
| July 2001-June 2002 Fellowship Little Rock, AR Clinical Trials Investigator Investigator in the University of Arkansas Department of Dermatology Clinical Trials Unit July 2001-June 2002 Physician Rogers, AR Worked part time for Robert R. Hull, M.D. seeing patients in primary care at his office. July 2000-June 2001 Internship Little Rock, AR Internship in Internal Medicine at the University of Arkansas for Medical Sciences. |
|
| EDUCATION |
1996-2000 Univ. of Arkansas for Medical Sciences Little Rock, AR 1994-1996 University of Arkansas Fayetteville, AR |
| 1990-1994 University of Arkansas Fayetteville, AR B.S., Biological Sciences Graduated magna cum laude |
|
| STATE LICENSURE | |
| Arkansas, 10/5/2001, E-3069. |
|
| RESEARCH | |
|
1996 Arkansas Children's Hospital Little Rock, AR 1994-1996 University of Arkansas Fayetteville, AR |
|
| SOCIETY MEMBERSHIPS | |
| 1996-present: American Medical Association 1996--present: Arkansas Medical Society 1997-present: American Academy of Dermatology 1999-present: Alpha Omega Alpha Honor Society 2001-present: Arkansas Dermatology Society 2003-present: Women's Dermatology Society 2002-present: American Society of Dermatologic Surgery 2005- present Benton County Medical Society |
|
| HONORS/AWARDS | |
| 1999- Alpha Omega Alpha Honor Society 1999- James Gentry Thomas Scholarship. Based on academic performance. 1998- Parent's Club Scholarship. Based on class nomination. 1997- Benton County Scholarship 1997, 1998- Barton Foundation Scholarship. Based on 4.0 Grade Point Average. 2000: W. Mage Honeycutt Dermatology Presentation Award. Presented by the Arkansas Dermatology Society. 2000: Outstanding Senior Dermatology Student Award. 2000: The Healthcare Foundation of New Jersey 2000 Humanism in Medicine Award. 2003: Women's Dermatology Society Mentorship Travel Award. |
|
| PUBLICATIONS | |
| Hull CA, Givens V, Smoller BR. Expression of the human erythrocyte glucose transporter Glut-1 in areas of sclerotic collagen in necrobiosis lipoidica. J Cutan Pathol. 2001 Jul;28(6):287-90. Hall G, Hull C, Siegel ER, Smoller BR, Johnson SM. Seasonal effect upon excision of acquired melanocytic proliferations. Intern J Dermatol 2002 Oct. Hershko, K, Hull C, Horn T, Gilliam AC. Nephrogenic fibrosing dermopathy variant with calcification and osteoclast-like giant cells. Hull C, Johnson B, Johnson SM. A double-blind comparative study of sodium sulfacetamide versus selenium sulfide for the treatment of Pityriasis versicolor. Cutis. |
|
| CHAPTERS | |
| North PE, Hull CA, Kincannon J: Vascular neoplasms and neoplastic-like proliferations, in Bolognia, Jorrizzo, Rapini (eds): Dermatology, 2003, London, Mosby. | |
| INDUSTRY SPONOSRED CLINICAL TRIALS | |
| Once a day XXX for the treatment of Pityriasis versicolor, 200-2002. A 6-month, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of XXX vs standard of care in the management of mild to severe atopic dermatitis in children 3 months to 11 years, 2002-2003. A randomized, double blind study comparing topically applied 0.03% XXX in pediatric subjects age 1 month to less than 24 months with moderate to severe atopic dermatitis, 2003. Multicenter dose ranging study of the safety and efficacy of XXX in psoriasis, 2002-2003. A Phase II randomized double-blind study to evaluate the dosing concentration and application frequency of XXX in the treatment of mild to moderate psoriasis in pediatric and adult subjects, 2002-2003. An open label, multicenter study of the safety and efficacy of XXX in psoriasis, 2003-2004. A phase 3, randomized, double-blind study to evaluate the efficacy and safety of once daily XXX versus vehicle in the treatment of psoriasis, 2003-2004. A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0 mg/kg subcutaneously administered XXX in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies, 2003-2004. A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when XXX is used at the first signs and/or symptoms of atopic dermatitis and it's safety and tolerability in adults 18 years of age and older, 2003-2004. |
|
